var data={"title":"Thiotepa: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Thiotepa: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7045?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=thiotepa-drug-information\" class=\"drug drug_general\">see &quot;Thiotepa: Drug information&quot;</a> and <a href=\"topic.htm?path=thiotepa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Thiotepa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50109503\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelosuppression:</b> Thiotepa may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of thiotepa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Carcinogenicity:</b> Thiotepa should be considered potentially carcinogenic in humans.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50047945\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tepadina</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050283\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050275\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=thiotepa-drug-information\" class=\"drug drug_general\">see &quot;Thiotepa: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual protocols; details concerning dosing in combination regimens should also be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: <b>Hematopoietic stem cell transplant (HSCT) for CNS malignancy (including neuroblastoma);combination chemotherapy:</b> Infants, Children, and Adolescents: IV: 300 mg/m<sup>2</sup>/dose daily for 3 days beginning 8 days prior to transplant <b>OR </b> 300 mg/m<sup>2</sup>/dose daily for 3 days beginning 5 days prior to transplant (Dunkel 2010; Finlay 2008; Gilheeney 2010; Grodman 2009; Kushner 2001; Kushner 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Bladder cancer:</b> Intravesical: 60 mg in 30 to 60 mL NS retained for 2 hours once weekly for 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Ovarian, breast cancer:</b> IV: 0.3 to 0.4 mg/kg every 1 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Effusions:</b> Intracavitary: 0.6 to 0.8 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; reduced dose may be warranted. Use may be contraindicated with existing renal impairment and should be limited to cases where benefit outweighs risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; reduced dose may be warranted. Use may be contraindicated with existing hepatic impairment and should be limited to cases where benefit outweighs risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment for hematologic toxicity:</b> Adults: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">WBC &le;3000/mm<sup>3</sup>: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Platelets &le;150,000/mm<sup>3</sup>: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Use may be contraindicated with pre-existing marrow damage and should be limited to cases where benefit outweighs risk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30124467\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tepadina: 15 mg (1 ea); 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tepadina: 15 mg (1 ea); 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227134\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050287\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">In children, thiotepa is associated with a high emetic potential at doses &ge;300 mg/m<sup>2</sup>; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bladder instillation: Adults: Instill by catheter directly into the bladder and retain for 2 hours; patients should reposition every 15 to 30 minutes for maximal exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: Adults: Intrathecal dilutions are preservative-free and should be used as soon as possible after preparation. After preparation, store intrathecal medications (until use) in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Further dilute reconstituted solution prior to administeration. Administer low doses (adult) as a rapid injection over 5 minutes; high doses (pediatric) have longer infusion times (eg, over 2- to 4-hour infusion); refer to specific protocols. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132739\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227163\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tepadina: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light; do not freeze. Reconstituted solution (10 mg/mL) is stable for 8 hours when stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Solution further diluted for infusion in NS is stable for 24 hours when stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F), or for 4 hours when stored at 25&deg;C (77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Generic product labeling: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Reconstituted solutions (10 mg/mL) are stable for up to 8 hours when stored under refrigeration. Solutions further diluted for infusion in NS should be used immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal thiotepa (off-label use/route): After preparation, keep intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050286\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of superficial tumors of the bladder; palliative treatment of adenocarcinoma of breast or ovary; control of pleural, pericardial, or peritoneal effusions caused by metastatic tumors (FDA approved in adults); has also been used for intrathecal treatment of leptomeningeal metastases (in adults) and as part of a conditioning regimen prior to autologous or allogeneic hematopoietic stem cell transplantation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3402289\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Thiotepa may be confused with thioguanine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson 2009) encourage the following safety measures for intrathecal chemotherapy:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Intrathecal medication should not be prepared during the preparation of any other agents</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; After preparation, keep in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227209\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As a preparative regimen prior to allogeneic or autologous hemtopoietic progenitor cell transplantation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Intracranial hemorrhage, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Mucositis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, hemorrhage, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Cytomegalovirus disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Other approved/nonapproved uses:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, contact dermatitis, dermatitis, skin depigmentation, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, anorexia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Cystitis, dysuria, hemorrhagic cystitis, inhibition of Spermatogenesis, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactic shock, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Asthma, laryngeal edema, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Febrile reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal gait, acute myelocytic leukemia, acute respiratory distress, acute sinusitis, amnesia, apathy, aphasia, arteriosclerosis (pulmonary arteriopathy), ascites, aspiration, ataxia, behavioral problems, blepharoptosis, blindness, blood coagulation disorder, blood platelet disorder (refractoriness to transfusion), bone marrow aplasia, bone marrow depression (bone marrow transplant rejection), bradycardia, brain disease, candidiasis, capillary leak syndrome, cardiac failure, cerebrovascular accident, cognitive dysfunction, coma, confusion, cranial nerve palsy, deafness, delirium, depression, diarrhea, disorientation, drowsiness, dysphagia, dyspnea on exertion, encephalitis, enterocolitis, epstein-barr infection, fever, forgetfulness, fungal infection, gastritis, gastroenteritis, gastrointestinal hemorrhage, hallucination, hematuria, hemiplegia, hepatomegaly, hyponatremia, hypotonia, immunosuppression, infection due to enterococcus, interstitial pulmonary disease, klebsiella species, lesion (including central nervous system and white matter), leukemia (recurrent), leukoencephalopathy, lower respiratory tract infection (viral), lymphoproliferative disorder (posttransplant), malaise, malignant lymphoma (including central nervous system lymphoma), malignant neoplasm (recurrence), malignant neoplasm of breast (metastatic), memory impairment, motor dysfunction, mouth disease (palatal disorder), myelodysplastic syndrome, neoplasm (metastatic), neurotoxicity, pain, papilledema, paralysis (retrobulbar), paresis (quadriparesis), pericardial effusion, pericarditis, pneumonitis, pseudomonas infection, psychomotor retardation, pulmonary aspergillosis, pulmonary disease, pulmonary hypertension, pulmonary veno-occlusive disease, pure red cell aplasia, renal failure, respiratory distress, respiratory tract infection, sepsis, septic shock, speech disturbance, staphylococcal bacteremia, staphylococcal infection, Stevens-Johnson Syndrome, strabismus, subarachnoid hemorrhage, subdural hematoma, suicidal ideation, thrombotic thrombocytopenic purpura (cerebral), toxic epidermal necrolysis, toxic nephrosis, tremor, urinary tract infection, vasodilatation (cerebral ventricle), ventricular hypertrophy, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227155\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity (allergy) to thiotepa or any component of the formulation; concomitant use with live or attenuated vaccines (Tepadina)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227138\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Myelosuppression (leukopenia, thrombocytopenia, and anemia) may commonly occur, particularly when used as part of the preparative regimen for hematopoietic stem cell transplantation (HSCT) or in patients with compromised bone marrow function. Do not initiate the HSCT conditioning regimen if a stem cell donor is not available. Monitor blood counts closely. Monitor for infection or bleeding; death due to septicemia and hemorrhage has occurred. Myelosuppression (including fatal cases) has also been reported with intravesicular administration (due to systemic absorption).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Fatal encephalopathy has been reported in patients receiving high-dose thiotepa. Headache, apathy, psychomotor retardation, disorientation, confusion, amnesia, hallucinations, drowsiness, somnolence, seizures, coma, inappropriate behavior, and forgetfulness have also been reported (may be dose dependent). If severe or life-threatening central nervous system toxicity occurs, discontinue treatment and manage as necessary. CNS toxicity, including seizures and intracranial hemorrhage was reported in pediatric patients who receive the recommended dose in combination with busulfan and cyclophosphamide as a stem cell conditioning regimen for beta thalassemia; do not exceed the recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: In patients receiving high-dose thiotepa, the parent drug and/or its active metabolites may be partially excreted through the skin. Thiotepa may cause skin discoloration, pruritus, blistering, desquamation, and peeling (may be more severe in skin folds, groin, axillae, and neck areas, and under dressings). Change occlusive dressing and clean covered skin at least twice daily during and for 48 hours after thiotepa administration (when used as a component of the HSCT preparative regimen). Patients should shower/bathe in water twice daily through 48 hours after receiving thiotepa. Change bed sheets daily. Accidental thiotepa exposure is also associated with skin reactions; wash skin thoroughly with soap and water and flush mucous membranes if skin and/or mucous membrane contact occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: In children, thiotepa is associated with a high emetic potential at doses &ge;300 mg/m<sup>2</sup> (Dupuis 2011) and is associated with a moderate emetic potential (depending on dose/indication) in adults (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting. Thiotepa is also associated with mucositis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic sinusoidal obstruction syndrome: Hepatic sinusoidal obstruction syndrome (SOS, also called veno-occlusive disease [VOD]) may occur in patients receiving thiotepa in combination with busulfan and cyclophosphamide as a preparative regimen prior to HSCT. Monitor serum transaminases, bilirubin and for signs/symptoms of hepatic SOS through day +28 of stem cell transplant; provide supportive care if SOS develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Clinically significant hypersensitivity reactions (including anaphylaxis) have occurred. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, discontinue thiotepa treatment and initiate appropriate supportive management. Monitor until resolution of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Thiotepa is potentially carcinogenic; myelodysplastic syndrome and acute myeloid leukemia (AML) have been reported. There is an increased risk of secondary malignancies with thiotepa use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; thiotepa is extensively hepatically metabolized; moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (bilirubin &gt;3 times ULN and any AST) impairment may result in increased plasma concentrations and increased toxicity. Monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; decreased renal excretion may result in increased thiotepa and TEPA plasma concentrations and increased toxicity. Monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Do not administer live or attenuated viral or bacterial vaccines until the immunosuppressive effects of thiotepa have resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal safety: When used for intrathecal administration (off-label route), should not be prepared during the preparation of any other agents. After preparation, keep intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the central nervous system (Jacobson 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227199\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227143\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12838&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Substrates (High risk with Inhibitors): Thiotepa may increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227145\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3881813\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, thiotepa may cause fetal harm if used in pregnant women. Verify pregnancy status in women of reproductive potential prior to therapy initiation. Effective contraception should be used during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during therapy and for at least 1 year after the final dose. Both male and female fertility may be affected by thiotepa administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050282\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, uric acid, urinalysis, renal and hepatic function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227137\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent (Perry 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227154\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 0.3 to 1.6 L/kg; penetrates into CSF (Maanen 2000); the mean volume of distribution following a single IV dose in pediatric patients receiving a 5 mg/kg dose was 1.2 L/kg or 30 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~10% to 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via cytochrome P450 system, primarily to the major (active) metabolite TEPA (Maanen 2000; Perry 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatrics (5 mg/kg IV dose): Thiotepa: 1.7 hours; TEPA: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (20 mg to 250 mg/m<sup>2</sup> IV dose): Thiotepa: 1.4 to 3.7 hours; TEPA: 4.9 to 17.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;2% of thiotepa dose; &lt;11% of TEPA)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323960\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tepadina Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $1,080.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $5,640.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Thiotepa Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $1,680.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038841\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ledertepa (BE, LU, NL);</li>\n      <li>Oncotiotepa (BE, LU);</li>\n      <li>Tepadina (BB, CZ, ES, FR, GB, HK, HR, HU, IE, KR, MT, NO, PL, TR);</li>\n      <li>Tespamin (JP, TW);</li>\n      <li>Thio-Tepa (AR, CZ);</li>\n      <li>Thiooplex (GR, IT);</li>\n      <li>Thiotepa Lederle (AT, CH, DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Dunkel IJ, Gardner SL, Garvin JH Jr, et al, &quot;High-Dose Carboplatin, Thiotepa, and Etoposide With Autologous Stem Cell Rescue for Patients With Previously Irradiated Recurrent Medulloblastoma,&quot; <i>Neuro Oncol</i>, 2010, 12(3):297-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/20167818/pubmed\" target=\"_blank\" id=\"20167818\">20167818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finlay JL, Dhall G, Boyett JM, et al, &quot;Myeloablative Chemotherapy With Autologous Bone Marrow Rescue in Children and Adolescents With Recurrent Malignant Astrocytoma: Outcome Compared With Conventional Chemotherapy: A Report From the Children's Oncology Group,&quot; <i>Pediatr Blood Cancer</i>, 2008, 51(6):806-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/18802947/pubmed\" target=\"_blank\" id=\"18802947\">18802947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilheeney SW, Khakoo Y, Souweidane M, et al, &quot;Thiotepa/Topotecan/Carboplatin With Autologous Stem Cell Rescue in Recurrent/Refractory/Poor Prognosis Pediatric Malignancies of the Central Nervous System,&quot; <i>Pediatr Blood Cancer</i>, 2010, 54(4):591-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/19998470/pubmed\" target=\"_blank\" id=\"19998470\">19998470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grodman H, Wolfe L, and Kretschmar C, &quot;Outcome of Patients With Recurrent Medulloblastoma or Central Nervous System Germinoma Treated With Low Dose Continuous Intravenous Etoposide Along With Dose-Intensive Chemotherapy Followed by Autologous Hematopoietic Stem Cell Rescue,&quot; <i>Pediatr Blood Cancer</i>, 2009, 53(1):33-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/19326417/pubmed\" target=\"_blank\" id=\"19326417\">19326417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grossman SA, Finkelstein DM, Ruckdeschel JC, et al, &quot;Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,&quot; <i>J Clin Oncol</i>, 1993, 11(3):561-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/8445432/pubmed\" target=\"_blank\" id=\"8445432\">8445432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &quot;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heideman R, Cole D, Balis F, et al, &quot;Phase I and Pharmacokinetic Evaluation of Thiotepa in the Cerebrospinal Fluid and Plasma of Pediatric Patients: Evidence for Dose-Dependent Plasma Clearance of Thiotepa,&quot; <i>Cancer Res</i>, 1989, 49(3):736-41. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/2491958/pubmed\" target=\"_blank\" id=\"2491958\">2491958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kletzel M, Abella EM, Sandler ES, et al, &quot;Thiotepa and Cyclophosphamide With Stem Cell Rescue for Consolidation Therapy for Children With High-Risk Neuroblastoma: A Phase I/II Study of the Pediatric Blood and Marrow Transplant Consortium,&quot; <i>J Pediatr Hematol Oncol</i>, 1998, 20(1):49-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/9482413/pubmed\" target=\"_blank\" id=\"9482413\">9482413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Cheung NK, Kramer K, et al, &quot;Topotecan Combined With Myeloablative Doses of Thiotepa and Carboplatin for Neuroblastoma, Brain Tumors, and Other Poor-Risk Solid Tumors in Children and Young Adults,&quot; <i>Bone Marrow Transplant</i>, 2001, 28(6):551-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/11607767/pubmed\" target=\"_blank\" id=\"11607767\">11607767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Kramer K, Modak S, et al, &quot;Topotecan, Thiotepa, and Carboplatin for Neuroblastoma: Failure to Prevent Relapse in the Central Nervous System,&quot; <i>Bone Marrow Transplant</i>, 2006, 37(3):271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/16400336/pubmed\" target=\"_blank\" id=\"16400336\">16400336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network&reg; (NCCN), &quot;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&quot; Version 2.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soussain C, Hoang-Xuan K, Taillandier L, et al, &quot;Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle Osseuse-Th&eacute;rapie Cellulaire,&quot; <i>J Clin Oncol</i>, 2008, 26(15):2512-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/18413641/pubmed\" target=\"_blank\" id=\"18413641\">18413641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepadina (thiotepa) [prescribing information]. Caponago (MB), Italy: Adienne SA; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thiotepa [prescribing information]. Bedford, OH: Bedford Laboratories; April 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12838 Version 124.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F50109503\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50047945\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050283\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050275\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F30124467\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F227134\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050287\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132739\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F227163\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050286\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3402289\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F227209\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F227155\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227138\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F227199\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F227143\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F227145\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3881813\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050282\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227137\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F227154\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323960\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038841\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12838|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=thiotepa-drug-information\" class=\"drug drug_general\">Thiotepa: Drug information</a></li><li><a href=\"topic.htm?path=thiotepa-patient-drug-information\" class=\"drug drug_patient\">Thiotepa: Patient drug information</a></li></ul></div></div>","javascript":null}